IGFBP3 and esophageal squamous cell carcinoma: Gefitinib resistance in ESCC was associated with diverse mechanisms, including RTK signalling via PDGFRβ and IGFBP3/IGF1/IGF1R, as well as EMT, but was consistently associated with the maintenance of signalling via AKT across multiple cell lines and model systems.